About
FluoTech Biosciences Limited emerges from groundbreaking research in Metal-Organic Framework (MOF) technology and drug delivery systems. Established in 2023 through the Hong Kong Science and Technology Park (HKSTP) program, we combine expertise in materials science and biomedical engineering to create revolutionary solutions for both research and theragnostic applications.
mission
To develop and commercialize cutting-edge nanomaterial platforms that address critical challenges in therapeutic delivery and advanced materials research, creating sustainable value across scientific and healthcare sectors.
vision
To revolutionize cardiovascular disease and Cancer treatments through innovative nanomaterial solutions while advancing materials science research globally.
Drug Delivery platform: ATHRICINE™ Therapeutic Platform
It is a therapeutic Innovation that uses MOF to deliver drugs to the target.
Advanced Research Materials:
FTB-728 Platform
A MOF platform with applications ranging from biomedical to environmental usage.